Nevertheless, the identification of the de novo GPHN mutation in a patient with a Dravet‐like syndrome is intriguing, since the GABAergic synapse is a well‐known major pathway for this phenotype: mutations in SCN1A, mainly expressed in inhibitory GABAergic interneurons, GABRA1, and GABRG2, all have previously been linked to Dravet syndrome (Hirose, 2014). Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.